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Serologic Survey 
of Pandemic 
(H1N1) 2009 Virus, 
Guangxi Province, 
China 
To the Editor: Since mid-April 
2009, a new inﬂ  uenza A virus (H1N1), 
now called  pandemic (H1N1) 2009 
virus, has caused inﬂ  uenza outbreaks 
in humans in North America (1) and 
a worldwide pandemic (2–4). Human 
pandemics occur when a new virus 
subtype emerges that is capable of 
human-to-human transmission in a 
population with little or no neutraliz-
ing antibodies to the new virus (4).
The current outbreak presents 
the  ﬁ   rst opportunity to directly ob-
serve this process. We used hemag-
glutination inhibition (HI) and virus 
neutralization (VN) assays to detect 
antibodies in 4,043 serum samples 
from residents (7–84 years of age) of 
2 counties in Guangxi Province, Peo-
ple’s Republic of China, collected dur-
ing July–August 2008. These persons 
were mostly farmers who lived in rural 
areas. Serum samples were obtained, 
transported, and frozen at –80°C as 
described (5). No participants had a 
history of vaccination against seasonal 
inﬂ  uenza. Antibodies were also detect-
ed in another 22 persons (<40 years of 
age) in Shantou, Guangdong Province, 
who had received 3 vaccinations for 
seasonal inﬂ  uenza since 2006.
Inﬂ  uenza viruses used in this study 
were A/California/04/2009 (H1N1; 
CA04), A/Brisbane/59/2007 (H1N1; 
B59), and A/swine/Hong Kong/915/
2004 (H1N2; Sw915). CA04 and B59 
were kindly provided by the World 
Health Organization Collaborating 
Centers for Reference and Research 
on Inﬂ  uenza (Atlanta, GA, USA, and 
Parkville, Victoria, Australia). Sw915 
was isolated from pigs by our labora-
tory. Seven of 8 genomic segments of 
Sw915 were located in a sister lineage 
to the current outbreak; this strain is 
the most closely related swine virus to 
CA04 identiﬁ  ed to date (6). All serum 
samples were treated with a receptor-
destroying enzyme and absorbed with 
fresh turkey erythrocytes to remove 
nonspeciﬁ   c inhibitors before the as-
says. All samples were tested by HI 
and VN assays according to standard 
protocols (5).
Screening by HI assay showed 
that 70 samples were positive (titers 
>40) for CA04 (Table). Examination 
by VN assay showed that of 70 HI-
positive serum samples, 12 had detect-
able neutralizing antibodies to CA04 
(positive rate 0.3%). Of these VN-pos-
itive samples, 10 had titers of 40–80 
and only 2 had neutralizing antibody 
titers >160 (Table). The 12 persons 
from whom the samples were obtained 
were 30–60 years of age. In contrast 
with ﬁ  ndings from a recent serologic 
survey of a US population (7), our re-
sults showed that none of the 583 per-
sons >60 years of age in our study was 
VN seropositive for CA04.
All 70 HI-positive samples for 
CA04 were also screened for neutral-
izing antibodies against Sw915. Thir-
teen samples collected from persons 
40–84 years of age were VN positive 
(titers 40–160). Of these 13 samples, 5 
were positive (VN titer >40) for CA04 
and 8 were negative. However, 7 CA04 
VN-positive samples were negative 
for Sw915. These ﬁ  ndings suggest that 
some cross-reactivity exists between 
CA04 and other Sw915-like H1 sub-
type viruses circulating in the pig popu-
lation in southern China, and that spo-
radic human infection with H1 swine 
viruses has occurred in rural China, 
where exposure to pigs is common.
In contrast, screening all 4,043 se-
rum samples with A/Brisbane/59/2007 
showed that 159 (3.9%) samples had 
HI titers >40, of which 116 (2.9%) 
had neutralizing antibodies (titer >40) 
(Table). Only 3 serum samples from 
persons >60 years of age were VN 
positive for B59. Because the study 
group was not vaccinated, these results 
likely reﬂ  ect natural infection rates for 
seasonal inﬂ  uenza virus (H1N1). The 
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22 serum samples from vaccinated 
persons had no neutralizing antibodies 
against CA04, but all had high sero-
conversion rates for B59 (Table).
Our results suggest that most 
persons in our study population from 
Guangxi, China, are seronegative for 
pandemic (H1N1) 2009 virus (1). 
Serum samples from only 0.3% of 
persons tested neutralized the novel 
CA/04 strain. This ﬁ  nding  contrasts 
with ﬁ  ndings from the United States 
that serum samples from ≈11% of 
unvaccinated persons had antibodies 
against CA04 (7). Furthermore, all 
CA04-positive persons in our study 
were <60 years of age; the US study 
reported a 33% seropositive rate for 
this age group.
These differences may have been 
caused by the high proportion of sea-
sonal inﬂ  uenza vaccination coverage 
in the United States when compared 
with results form our unvaccinated 
population from southern China. 
Therefore, we suggest that vaccina-
tion against seasonal inﬂ  uenza, rather 
than exposure to older, seasonal, inﬂ  u-
enza viruses (H1N1), which may be 
genetically and antigentically similar 
to pandemic (H1N1) 2009 virus, as 
suggested (7), might have generated 
partial protection against this new vi-
rus. No persons in our vaccinated con-
trol group had neutralizing antibodies 
against CA04.
We hypothesize that the absence 
of neutralizing antibodies in our con-
trol group, all of whom had been vacci-
nated 3 times, suggests that prolonged 
and repeated vaccination is required 
for partial immunity to CA04 or that 
older vaccines may confer some de-
gree of protection. If these serologic 
differences are indicative of increased 
susceptibility, we would expect higher 
infection attack rates in largely unvac-
cinated populations than in vaccinated 
populations in countries such as China.
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Table. Serum antibodies to pandemic (H1N1) 2009 virus A/California/04/2009 and 
influenza A virus (H1N1) A/Brisbane/59/2007 in unvaccinated and vaccinated persons, 
Guangxi Province, People’s Republic of China* 
No. (%) unvaccinated 
persons, n = 4,043 
No. (%) vaccinated† 
persons, n = 22 
Virus, titer  HI VN HI VN
Pandemic (H1N1) 2009 virus A/California/04/2009 
 40–80  64 10 0 0
>160 6 2 0 0
  Total  70 (1.7)  12 (0.3)  0 0
Influenza A virus (H1N1) A/Brisbane/59/2007 
 40–80  131 64 9 9
>160 28 52 10 11
  Total  159 (3.9)  116 (2.9)  19 (86)  20 (91) 
*HI, hemagglutination inhibition; VN, virus neutralization. 
†Persons were vaccinated starting in 2006 with influenza virus (H1N1) strains A/New 
Caledonia/20/1999, A/Solomon Islands/3/2006, and A/Brisbane/59/2007.  
1These authors contributed equally to this 
article.